CRISPR research deal will attract new business, says Oxford Genetics

By Flora Southey contact

- Last updated on GMT

(Image: Getty/Blablo101)
(Image: Getty/Blablo101)

Related tags: CRISPR, Mammalian cell culture

Oxford Genetics has signed a supply and licensing agreement for CRISPR engineered mammalian cell line with an unnamed ecommerce firm.

According to the multi-million pound research agreement, Oxford Genetics will employ its high throughput automated genomic engineering platform for CRISPR modification of mammalian cell lines.

“We have moved away from manual processing, which is the norm in this market, in favour of automated, scalable platforms,” ​said CEO Ryan Cawood.

“This approach means we are well positioned to deliver the large number of custom-engineered cell lines per year that the global market is forecast to need,” ​he added.

The bioprocessing support firm did not disclose its partner’s identity, but told us the company conducts the vast majority of its business through an online catalogue of products.

“For contractual reasons, we cannot say much beyond it is in the research field,” ​chief commercial officer Paul Brooks told us.

The UK-based firm expects the partnership to attract more CRISPR-related business, Brooks added: “It highlights our ability to cope with the capacity demanded by our partner for a provider of engineered cell lines.”

The mammalian CRISPR cell line engineering platform is Oxford Genetics’ most recent service offering. In 2016, the firm secured funding from Innovate UK to optimise its mammalian biomanufacturing processes​ and address viral vector scalability issues​. 

In August 2017​, the firm announced the expansion of its bioproduction services in the UK, as well as plans to invest in a US office. Four months later​, the company teamed with MeiraGTx to develop adeno-associated viruses (AAVs) at a manufacturing facility in Central London, UK.

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us

Products

View more

Webinars